Q-omics provides the consensus-scored INPP5K profile across patient tissues and cancer cell-line models. INPP5K expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, INPP5K is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, INPP5K RNA expression shows 18,301 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where INPP5K shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INPP5K — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INPP5K survival associations across molecular data types. INPP5K RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INPP5K RNA expression–survival associations across cancer types. High INPP5K expression shows unfavorable associations in ACC, but favorable associations in KIRC, PAAD, UCEC, BRCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for INPP5K RNA expression.
This table summarizes INPP5K tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for INPP5K. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INPP5K shows lower tumor expression in KICH, LUAD, LUSC, READ and COAD and higher tumor expression in HNSC. The KICH box plot shows higher INPP5K RNA expression in normal versus tumor tissue (log2 FC = −1.343, t-test p < 0.001).
This table shows molecular features associated with INPP5K in patient tissues and cancer cell lines. In patient samples, INPP5K shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, INPP5K RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
